Precise Insights

Advanced Data and AI for Gastric-Esophageal Cancer

On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.

See some of the 1000s of data elements we offer:

Structured Fields

Request a Demo

 

labs

Results from variety of patient tests

Visits

Oncology practice visits

Observations

Tumor-related observations plus vitals, biometrics, pain, and more

Procedures

Surgeries, radiation, biopsies, imaging, chemotherapy, etc

Medications

Start and end dates, brand vs. generic codes, dosage, duration, and cycles

Diagnoses

Disease state, status, severity, and metastasis

Expert Abstraction

Request a Demo

 

Biomarkers

Biomarker testing, results, and timing

Disease Progression

Directly-observed measures of critical endpoints

Adverse Events

Different types of adverse responses

Histology

Classification into multiple categories

Enriched Data

Request a Demo

 

Cost & Utilization

Adjudicated costs with linked claims data

Safety, Comorbidities

Pre-cancer and claims charge events

Specialty Pharmacy & Hub

Rx acquisition status details

Payer & Formulary

Drug tiers and coverage

Social Determinants

Social and physical environment factors

AI-Enriched Insights

Request a Demo

 

Date of Metastasis

Rules-based imputation of date of metastasis

Metastatic Status

Imputation of missing data from unstructured notes

Date of Initial Dx

Imputation of index event

Line of Therapy

Regimen or progression-based drug classes

Patient Adherence

Identify root cause of product switching

Patient Acquisition

Predict factors driving patients’ brand decision

Request Data Count

Explore ConcertAI datasets to see how many patients are in your disease area and meet study criteria.

gastric-esophageal cancer

Research Studies

Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.

gastric-esophageal cancer research study

Treatment Patterns and Outcomes in mGC

The 5-year survival rate for metastatic gastric cancer (mGC) is very low and long remissions are rare. This study examined treatment patterns, outcomes, and HER2 testing over time in mGC patients.

See Full Study
Methods

Retrospective Observational Study

Analysis
  • Progression-free survival
  • Overall survival
Patient Criteria Included:
  • Adults with no concurrent other malignancy
  • Diagnosis between 1/2004 and 7/2011
  • HER2 testing
Results

243

Eligible patients

0

Initially diagnosed at Stage IV 

Median Progression-free survival by line of therapy

0

Months – First line

0

Months – Second line

0

Months – Third line

Conclusion

Patients with mGC have PFS and OS similar to clinical trials. Treatment patterns reflect increasing testing of HER2 overexpression.

Annals of Oncology, 2012

Request a Demo